title: Safety of masitinib mesylate in healthy cats.
abstract: BACKGROUND
  Masitinib mesylate is a PO-administered tyrosine kinase inhibitor developed both for human and animal diseases with activity against both mutated and wild type forms of the c-kit receptor and platelet-derived growth factor receptors α and β, and is currently registered in Europe for the treatment of mast cell tumors in dogs.
  
  
  OBJECTIVE
  The objective of this study was to determine if healthy cats can tolerate administration of masitinib without clinically relevant adverse effects.
  
  
  METHODS
  Twenty healthy research colony-specific pathogen-free cats.
  
  
  METHODS
  This study was a prospective, randomized phase 1 clinical trial. Masitinib was administered PO to 20 healthy cats. Ten cats received 50 mg masitinib every other day for 4 weeks, and 10 cats received 50 mg masitinib daily for 4 weeks.
  
  
  RESULTS
  Clinically relevant proteinuria was noted in 2/20 (10%) cats (both treated daily), and neutropenia was noted in 3/20 (15%) (seen in both treatment groups). An increase in serum creatinine concentration and adverse gastrointestinal effects were noted in some cats.
  
  
  CONCLUSIONS
  Masitinib mesylate was tolerated in the majority of cats. Long-term administration and pharmacokinetic studies are needed to further assess the use of masitinib in cats.
authors.affiliation: College of Veterinary Medicine, Texas A&M University, College Station, TX, USA. mdaly@cvm.tamu.edu
authors.forename: M
authors.initials: M
authors.lastname: Daly
authors.forename: S
authors.initials: S
authors.lastname: Sheppard
authors.forename: N
authors.initials: N
authors.lastname: Cohen
authors.forename: M
authors.initials: M
authors.lastname: Nabity
authors.forename: A
authors.initials: A
authors.lastname: Moussy
authors.forename: O
authors.initials: O
authors.lastname: Hermine
authors.forename: H
authors.initials: H
authors.lastname: Wilson
mesh_terms: D000818:Animals; D001549:Benzamides; D002371:Cat Diseases / Q000097:blood / Q000139:chemically induced*; D002415:Cats; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule / Q000662:veterinary; D005260:Female; D008297:Male; D010880:Piperidines; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D013047:Specific Pathogen-Free Organisms; D013844:Thiazoles / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D001549:Benzamides; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D013844:Thiazoles; C526575:masitinib